Biofunctionalized nanoparticles: an emerging drug delivery platform for various disease treatments

Rajendran J.C. Bose; Soo Hong Lee; Hansoo Park

doi:10.1016/j.drudis.2016.06.005

Biofunctionalized nanoparticles: an emerging drug delivery platform for various disease treatments

Rajendran J.C. Bose
, Soo Hong Lee
, Hansoo Park

Department of Biomedical Engineering

Research output: Contribution to journal › Review article › peer-review

70 Scopus citations

Abstract

Biological barriers, such as phagocytosis and nonspecific distribution, are major factors limiting the clinical translation of nanomedicine. Biomimetic and bioengineering strategies have been used to overcome these challenges. In particular, natural cell membrane-based biofunctionalized nanoparticles (CMFNPs) have gained widespread attention owing to their cell surface mimetic characteristics and tailored nanomaterial features. These hybrid nanocarriers show strong potential for the delivery of myriad therapeutic agents. Herein, we highlight the most recent advances in CMFNP-based drug delivery systems and address the challenges and opportunities in the field.

Original language	English
Pages (from-to)	1303-1312
Number of pages	10
Journal	Drug Discovery Today
Volume	21
Issue number	8
DOIs	https://doi.org/10.1016/j.drudis.2016.06.005
State	Published - 1 Aug 2016

Access to Document

10.1016/j.drudis.2016.06.005

Cite this

@article{0e19063136654a00b202533513551f82,

title = "Biofunctionalized nanoparticles: an emerging drug delivery platform for various disease treatments",

abstract = "Biological barriers, such as phagocytosis and nonspecific distribution, are major factors limiting the clinical translation of nanomedicine. Biomimetic and bioengineering strategies have been used to overcome these challenges. In particular, natural cell membrane-based biofunctionalized nanoparticles (CMFNPs) have gained widespread attention owing to their cell surface mimetic characteristics and tailored nanomaterial features. These hybrid nanocarriers show strong potential for the delivery of myriad therapeutic agents. Herein, we highlight the most recent advances in CMFNP-based drug delivery systems and address the challenges and opportunities in the field.",

author = "Bose, \{Rajendran J.C.\} and Lee, \{Soo Hong\} and Hansoo Park",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd",

year = "2016",

month = aug,

day = "1",

doi = "10.1016/j.drudis.2016.06.005",

language = "English",

volume = "21",

pages = "1303--1312",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "8",

}

TY - JOUR

T1 - Biofunctionalized nanoparticles

T2 - an emerging drug delivery platform for various disease treatments

AU - Bose, Rajendran J.C.

AU - Lee, Soo Hong

AU - Park, Hansoo

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Biological barriers, such as phagocytosis and nonspecific distribution, are major factors limiting the clinical translation of nanomedicine. Biomimetic and bioengineering strategies have been used to overcome these challenges. In particular, natural cell membrane-based biofunctionalized nanoparticles (CMFNPs) have gained widespread attention owing to their cell surface mimetic characteristics and tailored nanomaterial features. These hybrid nanocarriers show strong potential for the delivery of myriad therapeutic agents. Herein, we highlight the most recent advances in CMFNP-based drug delivery systems and address the challenges and opportunities in the field.

AB - Biological barriers, such as phagocytosis and nonspecific distribution, are major factors limiting the clinical translation of nanomedicine. Biomimetic and bioengineering strategies have been used to overcome these challenges. In particular, natural cell membrane-based biofunctionalized nanoparticles (CMFNPs) have gained widespread attention owing to their cell surface mimetic characteristics and tailored nanomaterial features. These hybrid nanocarriers show strong potential for the delivery of myriad therapeutic agents. Herein, we highlight the most recent advances in CMFNP-based drug delivery systems and address the challenges and opportunities in the field.

UR - https://www.scopus.com/pages/publications/84975032514

U2 - 10.1016/j.drudis.2016.06.005

DO - 10.1016/j.drudis.2016.06.005

M3 - Review article

C2 - 27297732

AN - SCOPUS:84975032514

SN - 1359-6446

VL - 21

SP - 1303

EP - 1312

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 8

ER -

Biofunctionalized nanoparticles: an emerging drug delivery platform for various disease treatments

Abstract

Access to Document

Other files and links

Fingerprint

Cite this